13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q4 2021. See the latest, Q2 2026 →
Reported value
$4.14B
−1.7% on the quarter before
Positions
58
15 new · 0 sold out
Top 10
76.4%
of the value
Est. gain
−$1.00B
on stocks held all quarter
Est. return
−27.1%
on those stocks since Q3 2021
Positions as of Dec 31, 2021, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2021. Striped tiles are options.
Largest buys
Since Q3 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- IonQ~$365.8MNew · 0.0% → 8.8%+21,907,038 shares
- Toast~$329.6MNew · 0.0% → 8.0%+9,496,884 shares
- Eqrx Inc~$324.3MNew · 0.0% → 7.8%+47,552,687 shares
- Planet Labs Pbc~$196.4MNew · 0.0% → 4.7%+31,942,641 shares
- Freshworks Inc~$106.0MNew · 0.0% → 2.6%+4,035,595 shares
- 23andme Holding Co~$44.9MNew · 0.0% → 1.1%+6,736,785 shares
- Science 37 Holdings Inc~$40.4MNew · 0.0% → 1.0%+3,241,075 shares
- Enjoy Technology Inc~$20.1MNew · 0.0% → 0.5%+4,345,340 shares
- SentinelOne~$7.0MNew · 0.0% → 0.2%+138,503 shares
- Hyperfine Inc~$6.5MNew · 0.0% → 0.2%+898,720 shares
Largest sells
Since Q3 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- UiPath~$151.5MCut · 21.9% → 14.7%−3,512,754 shares
- Arcus Biosciences Inc~$62.2MCut · 3.4% → 2.5%−1,537,034 shares
- Duolingo Inc.~$60.3MCut · 2.8% → 0.4%−567,860 shares
- Dexcom Inc~$54.6MCut · 10.4% → 9.1%−101,670 shares
- Robinhood~$49.2MCut · 7.7% → 2.1%−2,768,800 shares
- Vera Therapeutics Inc~$6.2MCut · 0.4% → 0.5%−231,133 shares
- Rapt Therapeutics Inc~$3.0MCut · 0.5% → 0.6%−82,488 shares
- Relay Therapeutics Inc~$2.4MCut · 1.2% → 1.2%−77,324 shares
- Singular Genomics Systems Inc~$694,048Cut · 0.2% → 0.2%−60,038 shares
- Vaccitech Plc~$1,111Cut · 0.6% → 0.5%−100 shares
Holdings
As of Dec 31, 2021. Changes are in shares against Sep 30, 2021, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UiPathCL A · shares −20% · price −18.0% | 14.7% | $606.8M | −$133.4M | ||||||||
| Verve Therapeutics IncCOM · shares 0% · price −21.6% | 9.8% | $404.6M | −$111.2M | ||||||||
| Dexcom IncCOM · shares −13% · price −1.8% | 9.1% | $378.0M | −$6.9M | ||||||||
| IonQCOM · shares New | 8.8% | $365.8M | — | ||||||||
| ToastCL A · shares New | 8.0% | $329.6M | — | ||||||||
| Eqrx IncCOM · shares New | 7.8% | $324.3M | — | ||||||||
| Lyft IncCL A COM · shares 0% · price −20.3% | 6.3% | $262.3M | −$66.7M | ||||||||
| Planet Labs PbcCOM CL A · shares New | 4.7% | $196.4M | — | ||||||||
| Oscar Health IncCL A · shares 0% · price −54.9% | 4.6% | $188.7M | −$229.4M | ||||||||
| Benson Hill IncCOMMON STOCK · shares 0% · price +2.2% | 2.6% | $107.5M | +$2.4M | ||||||||
| Freshworks IncCLASS A COM · shares New | 2.6% | $106.0M | — | ||||||||
| Arcus Biosciences IncCOM · shares −37% · price +16.1% | 2.5% | $103.7M | +$14.4M | ||||||||
| RobinhoodCOM CL A · shares −36% · price −57.8% | 2.1% | $87.5M | −$119.9M | ||||||||
| Desktop Metal IncCOM CL A · shares 0% · price −31.0% | 1.3% | $54.7M | −$24.5M | ||||||||
| Relay Therapeutics IncCOM · shares −4.7% · price −2.6% | 1.2% | $48.0M | −$1.3M | ||||||||
| Lyell Immunopharma IncCOM · shares 0% · price −47.7% | 1.1% | $45.4M | −$41.4M | ||||||||
| 23andme Holding CoCLASS A COM · shares New | 1.1% | $44.9M | — | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price −31.3% | 1.1% | $43.5M | −$19.8M | ||||||||
| Adagio Therapeutics IncCOM · shares 0% · price −82.8% | 1.00% | $41.2M | −$198.7M | ||||||||
| Science 37 Holdings IncCOM · shares New | 0.98% | $40.4M | — | ||||||||
| Monte Rosa Therapeutics IncCOM · shares 0% · price −8.3% | 0.72% | $29.9M | −$2.7M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price −8.4% | 0.62% | $25.6M | −$2.4M | ||||||||
| Rapt Therapeutics IncCOM · shares −12% · price +18.3% | 0.56% | $23.1M | +$3.6M | ||||||||
| Illumina IncCOM · shares 0% · price −6.2% | 0.49% | $20.3M | −$1.3M | ||||||||
| Enjoy Technology IncCOM · shares New | 0.48% | $20.1M | — | ||||||||
| Total · 58 positions | 100% | $4.14B | −$1.00B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2021 to Q4 2021: 43 stocks held throughout, down $1.00B (−27.1%).
- Arcus Biosciences Inc+$14.4M+16%
- Vera Therapeutics Inc+$6.7M+54%
- Foghorn Therapeutics Inc+$4.5M+64%
- Rapt Therapeutics Inc+$3.6M+18%
- New Relic Inc+$3.5M+53%
- Verve Therapeutics Inc−$111.2M−22%
- Robinhood−$119.9M−58%
- UiPath−$133.4M−18%
- Adagio Therapeutics Inc−$198.7M−83%
- Oscar Health Inc−$229.4M−55%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |